Cartasteine is thioether derivative patented by Beijing Beipeng Technology Co. for resisting platelet aggregation and preventing or treating cardiovascular and cerebrovascular diseases

Cyacetacide is a biochemical used in the past as an anti-tuberculosis agent and currently used in Russia to for the treatment of various forms of tubercular lesions of the eye: keratitis, scleritis, uveitis, chorioretinitis, tuberculosis-allergic diseases and eye diseases of non-tubercular origin. Cyacetacide has also been used to derive compounds that may have antitumor properties.

Phencarbamide is an anti-spasmodic and anticholinergic drug used during parturition. It has a specific antispasmodic action on the smooth muscle, both directly like papaverine and through the autonomic nervous system (atropine effect). It has also an analgesic effect of its own. Side-effects generally associated with the atropine group of drugs.

Perzinfotel (EAA-090) is a novel squaric acid amide derivative that has been identified as a potential treatment for ischemic brain damage resulting from stroke. EAA-090 is a competitive inhibitor at the NMDA-selective subtype of the glutamate receptor. The compound demonstrates potent inhibitory activity in both in vitro and in vivo models of NMDA-induced excitotoxicity and provides neuroprotective efficacy in several animal models of stroke. EAA-090 is unique among competitive NMDA antagonists in displaying a clear separation between predicted efficacious dose and doses that induce PCP-like psychotomimetic side effects in both animals and humans. This unique profile makes EAA-090 an exciting candidate for assessing the neuroprotective potential of the competitive NMDA mechanism.

Roxibolone, an androstane derivative, possesses the anti-glucocorticoid activity and devoid of any affinity for the androgenic prostate and muscle receptors. This anabolic drug has never been marketed.

Crotoniazide is a derivative of isonicotinic hydrazide. Crotoniazide demonstrated antituberculous activity in vitro and in vivo.

Clinafloxacin is a broad-spectrum fluoroquinolone antibiotic that was originally developed and subsequently abandoned in the late 1990s as a human health antibiotic for respiratory diseases. Clinafloxacin displays broad-spectrum antibacterial activity against Gram-positive, Gram-negative, and anaerobic pathogens by inhibiting the bacterial regulatory enzyme DNA gyrase (IC50 = 0.92 ug/ml) as well as topoisomerase IV (IC50 = 1.62 ug/ml).

Glycovir (SC-49483) is an ester produg (a biologically inactive compound that can be metabolized in the body to produce a drug) of SC 48334, an α-glycosidase 1 inhibitor that has anti-HIV activity. Glycovir was thus studied for treatment in HIV. It is targeted against viral glycoprotein processing in host cell endoplasmic reticulum. Bioavailability of the pharmacologically active SC-48334 observed after glycovir administration was found to be very different between species, but monkeys are a good animal model for prediction of bioavailability of SC-48334 in humans. A phase II trial was conducted to determine the safety and anti-HIV activity of a combination treatment of glycovir with zidovudine (AZT).